ValiRx is building a portfolio of innovative products through strategic investment in projects related to the treatment and diagnosis of cancer, inflammatory disease and inherited genetic disorders or indeed in companies with complementary technologies. ValiRx aims to deliver high returns by applying its scientific, management and entrepreneurial expertise to projects in which it has equity and rights. These projects tend to have low acquisition and manageable development costs with the potential to significantly increase in value prior to value crystallisation.

The diversity of projects that ValiRx is undertaking spreads the investment risk. Moreover, the business model minimises the level of financial exposure associated with R&D since the bulk of the costs are borne by its academic partners in return for a royalty payment or, in the case of a commercial partner, an exclusive licensing agreement from which ValiRx derives revenue in the form of milestone and royalty payments.